What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Biogen Inc. raised its annual earnings guidance after reporting better-than-expected third-quarter sales and profit, driven ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Biogen's (NASDAQ:BIIB) partner for intravenous Alzheimer's therapy, Leqembi, has completed the rolling submission of a ...

Biogen raised annual profit forecast and beat third-quarter profit expectations on Wednesday, as its cost-cutting measures ...

Biogen reported mixed third-quarter results, with EPS beating expectations despite a decline in total revenue.

Even though Biogen raised earnings guidance, the company still has “some potentially concerning signals” in its base business ...

Leqembi, along with rare disease and depression treatments, helped offset a year-over-year decline in revenue for the company ...

Biogen touted strong Q3 sales of its Alzheimer’s drug Leqembi a day after announcing a deal worth up to $1.45 billion with ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA ...

Biogen raised its annual profit forecast on Wednesday, as new treatments and cost-cutting measures offset declining sales of its multiple sclerosis drugs.

Biogen and Neomorph have partnered to discover and develop molecular glue degraders for treating Alzheimer’s and other rare ...